Last €18.30 EUR
Change Today +0.10 / 0.55%
Volume 273.8K
QIA On Other Exchanges
Symbol
Exchange
Xetra
NASDAQ GS
As of 11:35 AM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

qiagen n.v. (QIA) Snapshot

Open
€18.15
Previous Close
€18.20
Day High
€18.35
Day Low
€18.08
52 Week High
09/9/14 - €18.83
52 Week Low
04/15/14 - €14.03
Market Cap
4.3B
Average Volume 10 Days
319.0K
EPS TTM
€0.89
Shares Outstanding
232.3M
EX-Date
--
P/E TM
26.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for QIAGEN N.V. (QIA)

qiagen n.v. (QIA) Related Businessweek News

No Related Businessweek News Found

qiagen n.v. (QIA) Details

QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. It offers approximately 500 core consumable products, such as sample and assay kits, and automated instrumentation systems that empower customers to transform raw biological samples into molecular information. The company’s consumable products are used for plasmid deoxyribonucleic acid (DNA) purification, and ribonucleic acid purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. The company sells the digene HC2 HPV Test, a test for high-risk strains of the human papillomavirus. It also offers co-development services for companion diagnostics, technology licensing and patent sales services, and custom services, including whole genome amplification, DNA sequencing, and non-cGMP DNA production on a contract basis. In addition, the company provides instrumentation systems that automate the use of sample and assay technologies into solutions for a range of laboratory needs enabling customers to perform nucleic acid sample preparation, assay setup, and target detection, as well as workflow solutions. Its automated systems include QIAsymphony, a modular system; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform; QIAcube, a sample processing instrument; QIAxcel for nucleic acid separation; and ESE-Quant Tube Scanners, an optical measurement device. The company serves molecular diagnostics laboratories; applied testing customers; pharmaceutical research and development groups, and academic researchers. It has a collaboration agreement with AstraZeneca PLC for the co-development and commercialization of a liquid biopsy-based companion diagnostic. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.

4,200 Employees
Last Reported Date: 07/30/14
Founded in 1986

qiagen n.v. (QIA) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: $1.5M
Chief Financial Officer, Managing Director an...
Total Annual Compensation: $639.5K
Compensation as of Fiscal Year 2013.

qiagen n.v. (QIA) Key Developments

Qiagen NV Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 12:20 PM

Qiagen NV Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 12:20 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

QIAGEN N.V. Enters into Distribution and Service Agreement with BGI Tech Solutions Co., Ltd

QIAGEN N.V. and BGI Tech Solutions Co., Ltd. have entered into a distribution and service agreement for the Human Gene Mutation Database (HGMD) in Greater China. Under the agreement, BGI Tech will serve the Chinese market including providing first level support for the database. HGMD is a unique resource providing comprehensive data on human inherited disease mutations for genetics and genomic research. It enables quick access to both single mutation queries and advanced search applications. Offered by BIOBASE, a QIAGEN company, HGMD is assembled by highly qualified subject-matter experts and organized in an accessible and easily searchable manner that enables scientists and clinical labs to identify connections between disparate pieces of information and apply that knowledge. It is widely used in human genetics research, diagnostics, and personal genomics applications and was an essential tool in analyzing the genomes assembled by the 1,000 Genomes Project. Expert-curated hereditary variants from HGMD are now available to customers using QIAGEN's Ingenuity Variant Analysis. Key features of HGMD include: 152,000+ mutation reports including specifics on genome coordinates, sequence details, and links to the source reference as well as public resources like dbSNP and OMIM; 5,300+ summary reports listing all known inherited disease mutations for a given gene characterized by six different pathogenic variant classes; advanced search functionality, including the ability to find mutations based on the type of nucleotide or amino acid change, or their location in a specific motif, splice site, or regulatory region; a mutation visualization tool which provides a graphical representation of the aligned DNA and protein sequences with color-coded mutated nucleotides for a selected gene; and ability to export customized mutation tracks for use in third-party genome browsers and analysis tools.

Qiagen NV Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter of 2014; Reaffirms Earnings Guidance for the Full Year of 2014

Qiagen NV reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net sales of $330,837,000 against $315,212,000 for the same period in the last year. Income from operations was $47,692,000 against loss from operations of $34,161,000 for the same period in the last year. Income before income taxes was $39,185,000 against loss before income taxes of $46,654,000 for the same period in the last year. Net income attributable to the owners of the company was $32,834,000 or $0.14 per basic and diluted share against net loss attributable to the owners of $51,761,000 or $0.22 per basic and diluted share for the same period in the last year. Operating income, adjusted was $81.2 million and net income, adjusted was $60.9 million or $0.25 per share against operating income, adjusted of $73.5 million and net income, adjusted of $56.1 million or $0.24 per share for the same period a year ago. For the six months, the company reported net sales of $647,910,000 against $618,788,000 for the same period in the last year. Income from operations was $89,995,000 against loss from operations of $5,090,000 for the same period in the last year. Income before income taxes was $67,024,000 against loss before income taxes of $23,874,000 for the same period in the last year. Net income attributable to the owners of the company was $56,102,000 or $0.23 per diluted share against net loss attributable to the owners of $31,778,000 or $0.14 per basic and diluted share for the same period in the last year. Net cash provided by operating activities was $119,214,000 against $93,832,000 for the same period in the last year. Purchases of property, plant and equipment were $42,491,000 against $33,695,000 for the same period in the last year. Purchases of intangible assets were $5,157,000 against $15,663,000 for the same period in the last year. Operating income, adjusted was $156.0 million and net income, adjusted was $114.7 million or $0.47 per share against operating income, adjusted of $143.3 million and net income, adjusted of $104.2 million or $0.43 per share for the same period a year ago. The company provided earnings guidance for the third quarter of 2014. For the third quarter of 2014, adjusted net sales are expected to raise approximately 4% to 5% at constant exchange rates, with adjusted diluted EPS of $0.26 to $0.27 at constant exchange rates compared to $0.26 in the year-ago quarter (under new adjustment policy). The company reaffirmed earnings guidance for the full year of 2014. For the full year, adjusted net sales are expected to rise approximately 4% to 5% at constant exchange rates, as sales growth of approximately 8% to 9% at constant exchange rates from the current business portfolio, as well as contributions from the bioinformatics acquisitions, exceed an adverse impact of up to approximately 4 percentage points from reduced sales of HPV products in the U.S. Adjusted diluted earnings per share (EPS) are expected to rise to approximately $1.07 to $1.09 at constant exchange rates for 2014 compared to $1.02 per share in 2013 (including share-based compensation for both years as part of the new adjustment policy). The company continued to expect about $120 million for amortization of acquired intellectual property and about $10 million to $15 million for business integration and acquisition and an adjusted tax rate of about 20% to 21%, and this is expected to be at the higher end of this range.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QIA:GR €18.30 EUR +0.10

QIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMerieux €81.47 EUR -0.03
Cepheid $44.39 USD +0.95
Hologic Inc $24.66 USD -0.14
Myriad Genetics Inc $38.12 USD +0.11
PerkinElmer Inc $44.30 USD +0.55
View Industry Companies
 

Industry Analysis

QIA

Industry Average

Valuation QIA Industry Range
Price/Earnings 42.2x
Price/Sales 4.1x
Price/Book 2.0x
Price/Cash Flow 41.5x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.